Human post‐infection serological response to the spike and nucleocapsid proteins of SARS‐CoV‐2

To inform seroepidemiological studies, we characterized the IgG‐ responses in COVID‐19 patients against the two major SARS‐CoV‐2 viral proteins, spike (S) and nucleocapsid (N). We tested 70 COVID‐19 sera collected up to 85 days post‐symptom onset and 230 non‐COVID‐19 sera, including 27 SARS sera fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Cheng, Ling, Shiman, Qiu, Minshan, Deng, Zhenxuan, Chen, Liping, Zhu, Airu, Chen, Yi, Liu, Yong, Lin, Xia, Lin, Fangmei, Wu, Qiubao, Shen, Lihan, Ye, Feng, Liu, Xiaoqing, Li, Yimin, Zhao, Jincun, Yang, Zifeng, Cowling, Benjamin J., Webby, Richard, Zanin, Mark, Wong, Sook‐San
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461388/
https://www.ncbi.nlm.nih.gov/pubmed/32844604
http://dx.doi.org/10.1111/irv.12798
Descripción
Sumario:To inform seroepidemiological studies, we characterized the IgG‐ responses in COVID‐19 patients against the two major SARS‐CoV‐2 viral proteins, spike (S) and nucleocapsid (N). We tested 70 COVID‐19 sera collected up to 85 days post‐symptom onset and 230 non‐COVID‐19 sera, including 27 SARS sera from 2003. Although the average SARS‐CoV‐2 S and N‐IgG titers were comparable, N‐responses were more variable among individuals. S‐ and N‐assay specificity tested with non‐COVID‐19 sera were comparable at 97.5% and 97.0%, respectively. Therefore, S will make a better target due to its lower cross‐reactive potential and its' more consistent frequency of detection compared to N.

Ejemplares similares